Z-VEID-FMK: Irreversible Caspase-6 Inhibitor for Apoptosis and Disease Models

Executive Summary: Z-VEID-FMK (CAS No. 210344-96-0) is a synthetic, cell-permeable, irreversible inhibitor with high specificity for caspase-6, a cysteine protease central to apoptosis regulation (APExBIO). This fluoromethyl ketone derivative achieves covalent binding at the caspase-6 active site, blocking proteolytic activity and substrate cleavage. Z-VEID-FMK is insoluble in water but dissolves in DMSO (≥113.4 mg/mL) and ethanol (≥3.01 mg/mL) with gentle warming and sonication. It is validated by HPLC, MS, and NMR for >94% purity, and is widely employed in neuronal and immune cell apoptosis models, as well as cancer and neurodegenerative disease research (Padia et al., 2025).

Biological Rationale

Caspase-6 is a member of the cysteine-aspartic acid protease family (ICE-like proteases) involved in the execution phase of apoptosis. Activation of caspase-6 leads to cleavage of nuclear lamins and structural proteins, resulting in chromatin condensation and nuclear fragmentation (APExBIO). Caspase-6 activity is implicated in disease pathways including cancer progression, neurodegeneration, and immune cell regulation (Padia et al., 2025). In neuronal models, excessive caspase-6 activation correlates with axonal degeneration and cell death. In cancer models, caspase cascade modulation can influence tumor cell survival, especially under stimuli like TNFα or Fas ligand. The ability to selectively inhibit caspase-6 enables researchers to dissect its unique contributions to apoptotic and non-apoptotic signaling.

Mechanism of Action of Z-VEID-FMK

Z-VEID-FMK is a tetrapeptide fluoromethyl ketone (FMK) derivative that irreversibly inhibits caspase-6 by covalently binding to the catalytic cysteine residue within the enzyme's active site. This interaction permanently inactivates caspase-6 proteolytic function, preventing downstream cleavage of substrates such as nuclear lamins and cytoskeletal proteins. The VEID peptide sequence confers high selectivity for caspase-6 versus related caspases. Cell permeability is achieved through peptide backbone modifications, enabling efficient intracellular delivery in both adherent and suspension models. Irreversible inhibition ensures sustained pathway blockade during experimental timeframes (typically 6 hours at 37°C, 50 μM in cell culture). The compound’s mechanism distinguishes it from reversible inhibitors, facilitating clear mechanistic studies of caspase-6-dependent events (APExBIO).

Evidence & Benchmarks

• Z-VEID-FMK achieves >94% purity as validated by HPLC, mass spectrometry, and NMR under standard analytical protocols (APExBIO).
• It selectively and irreversibly inhibits caspase-6 activity in cell lysates and live-cell contexts at 50 μM, 6 hours, 37°C (Padia et al., 2025).
• Downstream inhibition of nuclear lamin cleavage and apoptotic nuclear morphology is observed in treated neuronal and cancer cell lines (Z-VEID-FMK Disease Modeling Guide).
• Stock solutions remain stable at -20°C for short-term use (≤4 weeks) in DMSO or ethanol; activity decreases with repeated freeze-thaw cycles (APExBIO).
• In cell culture, Z-VEID-FMK supports apoptosis assays with high reproducibility and low cytotoxicity in the absence of apoptotic stimuli (Lamin Fragment Research Portal).

This article extends the functional benchmarks and troubleshooting guidance detailed in 'Z-VEID-FMK: Precision Caspase-6 Inhibitor for Apoptosis A…' by providing updated purity data and validated storage parameters.

Applications, Limits & Misconceptions

Z-VEID-FMK is widely applied in:

• Neuronal apoptosis research: Inhibition of caspase-6-dependent axon degeneration and neuronal cell death (Padia et al., 2025).
• Cancer research: Dissection of caspase-6-mediated apoptosis in tumor cell models, especially under TNFα or Fas ligand induction.
• Neurodegenerative disease modeling: Evaluation of caspase-6's role in pathologies such as Alzheimer's and Huntington's disease.
• Apoptosis assays: Quantification of caspase-6 activity and downstream substrate cleavage in vitro and in situ.
• Caspase signaling pathway analysis: Investigation of ICE-like protease inhibition and interplay with other caspase family members.

While Z-VEID-FMK is robust, several boundaries apply:

Common Pitfalls or Misconceptions

• Not a pan-caspase inhibitor: Z-VEID-FMK is selective for caspase-6 and does not significantly inhibit caspase-1, -3, or -8 at recommended concentrations.
• Ineffective in water-based stock solutions: The compound is insoluble in water; only DMSO or ethanol (with gentle warm/sonication) should be used for stocks.
• Does not block pyroptosis driven by caspase-1: Studies show that caspase-1-dependent cell death is unaffected by caspase-6 inhibitors (Padia et al., 2025).
• Loss of activity with repeated freeze-thaw: Enzyme inhibition declines if stock solutions undergo multiple freeze-thaw cycles; aliquot and store at -20°C.
• Not validated for in vivo systemic administration: Published data focus on cell culture and ex vivo assays; in vivo pharmacokinetics and toxicity are uncharacterized.

This article clarifies distinctions from 'Z-VEID-FMK: Irreversible Caspase-6 Inhibitor for Apoptosi…' by explicitly outlining usage boundaries and potential pitfalls in complex disease models.

Workflow Integration & Parameters

Optimal use of Z-VEID-FMK requires the following parameters:

• Dissolve compound in DMSO (≥113.4 mg/mL) or ethanol (≥3.01 mg/mL) at room temperature with gentle warming and sonication as needed.
• Prepare stock solutions in single-use aliquots; store at -20°C and avoid light exposure.
• For cell culture, use 50 μM final concentration with 6-hour incubation at 37°C.
• Include DMSO/ethanol solvent controls in all experimental designs.
• Monitor caspase-6 activity via fluorometric or colorimetric assays to confirm inhibition.
• For apoptosis studies, assess downstream markers such as nuclear lamin cleavage and Annexin V/PI staining.

Z-VEID-FMK is shipped on blue ice to preserve stability. For detailed protocol enhancements and troubleshooting, see the 'Strategic Caspase-6 Inhibition for Translational Models' article, which this resource updates by incorporating recent analytical validation and application limits.

Conclusion & Outlook

Z-VEID-FMK (APExBIO, A1923) is a benchmark irreversible caspase-6 inhibitor for apoptosis pathway analysis. Its specificity, robust analytical validation, and defined application parameters support reproducible research in cancer, neurodegeneration, and cell signaling. Careful attention to solvent, storage, and assay conditions ensures maximal inhibitor performance. Future development may expand its use in in vivo models and combinatorial pathway studies. For detailed product specifications and ordering, visit the Z-VEID-FMK product page.